A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-hodgkin lymphoma

Clinical Cancer Research

Volumn 20, Issue 1, 2014, Pages 213-220

  Ribrag, Vincent ^a   Dupuis, Jehan ^b   Tilly, Herve ^c   Morschhauser, Franck ^d   Laine, Fabrice ^e   Houot, Roch ^e   Haioun, Corinne ^b   Copie, Christiane ^b   Varga, Andrea ^a   Lambert, John ^h   Hatteville, Laurence ^f   Ziti Ljajic, Samira ^f   Caron, Anne ^f   Payrard, Sandrine ^f   Coiffier, Bertrand ^g  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c CENTRE HENRI BECQUEREL   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^f SANOFI   (France)

^g UNIVERSITÉ LYON 1   (France)

^h IMMUNOGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CD19 ANTIBODY; GAMMA GLUTAMYLTRANSFERASE; PARAPROTEIN; SAR 3419; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLERGIC PNEUMONITIS; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; BLURRED VISION; CHOLESTASIS; CLINICAL ARTICLE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CORNEA DISEASE; DIARRHEA; DIPLOPIA; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE IRRITATION; EYE TOXICITY; FATIGUE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEART LEFT BUNDLE BRANCH BLOCK; HUMAN; HUMAN TISSUE; IMMUNOGENICITY; INJECTION SITE REACTION; LARGE CELL LYMPHOMA; LEUKOENCEPHALOPATHY; LEUKOPENIA; LIVER TOXICITY; LOBAR PNEUMONIA; LOW DRUG DOSE; LUNG DISEASE; MALE; MIDDLE AGED; MUSCULOSKELETAL DISEASE; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OPEN STUDY; OPTIC NERVE DISEASE; OPTIMAL DRUG DOSE; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN TARGETING; RECOMMENDED DRUG DOSE; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; UVEITIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ASTHENIA; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY; LIVER; LYMPHOMA, B-CELL; MALE; MAXIMUM TOLERATED DOSE; MAYTANSINE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME;

EID: 84892172931     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0580     Document Type: Article

References (46)

1. Teicher BA, Chari RV. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res 2011;17:6448-6458.
2. Kreitman RJ, Pastan I. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res 2011;17:6398-405.
3. Ricart AD. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res 2011;17:6417-27.
4. Leonard JP, Goldenberg DM. Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies. Oncogene 2007;26:3704-13.
5. Polson AG, Ho WY, Ramakrishnan V. Investigational antibody-drug conjugates for hematological malignancies. Expert Opin Investig Drugs 2011;20:75-85.
6. Gerber HP, Kung-Sutherland M, Stone I, Morris-Tilden C, Miyamoto J, McCormick R, et al. Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab sensitive and -resistant lymphomas. Blood 2009;113:4352-61.
7. Topp M, Goekbuget N, Zugmaier G, Viardot A, Stelljes M, Neumann S, et al. Effect of anti-CD19 BiTE blinatumomab on complete remission rate and overall survival in adult patients with relapsed/refractory Bprecursor ALL. J Clin Oncol 2012;30: abstract 6500.
8. Winderlich M, Ness D, Steidl S, Endell J. Evaluation of combination therapies with MOR00208, an Fc-enhanced humanized CD19 antibody, in models of lymphoma. J Clin Oncol 2012;30: abstract 6574.
9. Blanc V, Bousseau A, Caron A, Carrez C, Lutz RL, Lambert JM. SAR3419: An anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res 2011 17:6448-6458.
10. de Rie MA, Schumacher TN, van Schijndel GM, van Lier RA, Miedema F. Regulatory role of CD19 molecules in B-cell activation and differentiation. Cell Immunol 1989;118:368-381.
11. Stamenkovic I, Seed B. CD19, the earliest differentiation antigen of the B cell lineage, bears three extracellular immunoglobulin-like domains and an Epstein-Barr virus-related cytoplasmic tail. J Exp Med 1988;168:1205-10.
12. Del Nagro CJ, Otero DC, Anzelon AN, Omori SA, Kolla RV, Rickert RC. CD19 function in central and peripheral B-cell development. Immunol Res 2005;31:119-31.
13. Nadler LM, Anderson KC, Marti G, Bates M, Park E, Daley JF, et al. B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J Immunol 1983; 131:244-50.
14. Scheuermann RH, Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma 1995;18:385-97.
15. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens onleukemias and lymphomas: a model of human B cell differentiation. Blood 1984;63:1424-33.
16. Widdison WC, Wilhelm SD, Cavanagh EE, Whiteman KR, Leece BA, Kovtun Y, et al. Semisynthetic maytansine analogues for the treatment of cancer. J Med Chem 2006; 49:4392-08.
17. Lopus M, Oroudjev E, Wilson L, Wilhelm S, Widdison W, Chari R, et al. Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. Mol Cancer Ther 2010; 9:2689-99.
18. Oroudjev E, Lopus M, Wilson L, Audette C, Provenzano C, Erickson H, et al. Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. Mol Cancer Ther 2010;9:2700-13.
19. Lambert JM. Antibody-maytansinoid conjugates: a new strategy for the treatment of cancer. Drugs Future 2010;35:471-80.
20. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol 2010;14:529-37.
21. Younes A. Beyond chemotherapy: new agents for targeted treatment of lymphoma. Nat Rev Clin Oncol 2010;8:85-96.
22. Erickson HK, Widdison WC, Mayo MF, Whiteman K, Audette C, Wilhelm SD, et al. Tumor delivery and in vivo processing of disulfide- linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem 2010;21:84-92.
23. Erickson HK, Provenzano CA, Mayo MF, Widdison WC, Audette C, Leece B, et al. Target-cell processing of the anti-CD19 antibody maytansinoid conjugate SAR3419 in preclinical models [abstract]. In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 5473.
24. Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003;102:1458-65.
25. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812-21.
26. Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E, et al. Safety, Pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-Cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 2010;28:2085-2093.
27. Dornan D, Bennett F, Chen Y, Dennis M, Eaton D, Elkins K, et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti- CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood 2009;114:2721-2729.
28. Lee JW, Stone RL, Lee SJ, Nam EJ, Roh JW, Nick AM, et al. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res 2010;16:2562-2570.
29. Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatice breast cancer. J Clin Oncol 2010;28:2698-2704.
30. Smith LM, Nesterova A, Alley SC, Torgov MY, Carter PJ. Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97. Mol Cancer Ther 2006;5:1474-1482.
31. Lutz RJ, Zuany-Amorim C, Vrignaud P, Mayo MF, Guerif S, Xie H, et al. Preclinical evaluation of SAR3419 (huB4-DM4), an anti-CD19-maytansinoid immunoconjugate, for the treatment of B-cell lymphoma. Proc Am Assoc Cancer Res 2006;47:3731.
32. Al-Katib AM, Aboukameel A, Mohammad R, Bissery MC, Zuany- Amorim C. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma. Clin Cancer Res 2009;15:4038-45.
33. Younes A, Kim S, Romaguera J, Copeland A, de castro Farial S, Kwak LW, et al. Phase I multi-dose escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J Clin Oncol 2012;30:2776-82.
34. Coiffier B, Ribrag V, Dupuis J, Tilly H, Haioun C, Morschhauser F, et al. Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients with relapsed / refractory B-cell non-Hodgkin's lymphoma (NHL). J Clin Oncol 29, 2011; (suppl; abstr 8017.
35. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of international workshop to standardize response criteria for non-hodgkin's lymphomas. J Clin Oncol 1999;17:1244-53.
36. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586.
37. ADCETRIS [Prescribing Information]. Bothell, WA: Seattle Genetics Inc; 2012.
38. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012;30:2183-2189.
39. Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol 2010;6:657-666.
40. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubulestabilizing agents. J Clin Oncol 2006;24:1633-42
41. Rivera E, Lee J, Davies A. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. The Oncologist 2008;13:1207-23
42. Swain SM, Arezzo JC. Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. Clin Adv Hematol Oncol 2008;6:455-67.
43. Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, et al. Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002;8:1038-44.
44. Burris HA III, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011;29:398-405.
45. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-803.
46. Ramos M, Gonzales-Ageitos A, Amendo M, Gonzales-Quintas A, Gamazo JL, Togores P, et al. Weekly docetaxel as second-line therapy for patients with advanced breast cance resistant to previous athracycline treatment. J Chemother 2003;15:192-7.